REG - BSF Enterprise PLC - 3D Bio-Tissues Appoints Business Director

BSF EnterpriseAnnouncement

21/09/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220921:nRSU0586Aa&default-theme=true

RNS Number : 0586A  BSF Enterprise PLC  21 September 2022

21 September 2022

BSF Enterprise PLC

("BSF" or the "Company")

3D Bio-Tissues Appoints Business Director to Commercialise City-mix™ growth
agent for Lab-Grown Meat and Leather

BSF Enterprise, an investment company focused on unlocking the next generation
of biotech solutions and the development of lab-grown tissues, is pleased to
announce that its 100% owned subsidiary, 3D Bio-Tissues (3DBT), has appointed
Robert Brownlee, as Business Director.

 

Mr. Brownlee is a highly experienced director with 15 years' experience of
bringing brands in the Biotech, Clinical and Pharmaceutical industries from
product launch to market leading status and will be focused on launching and
driving the ongoing commercialisation of 3DBT's proprietary serum-free media
concentrate, City-mix™, an animal-free cell growth agent for culturing skin,
muscle and fat cells for lab-grown meat and leather. Based in Leicestershire,
Robert will be working with the 3DBT team to develop a "go to market strategy"
and establish global sales channels.

 

Mr. Brownlee has held business development roles world-wide, previously
heading up European sales at PeproTech EC, part of Thermo Fisher Scientific.
In addition, at Technopath, part of Diploma plc, he led a newly merged
Laboratory Sciences Division - amalgamating the Clinical, Biotech and Pharma
Divisions - and achieving substantial revenue growth. Here, he also helped
develop and implement sales strategies to take Technopath's Multichem range of
products from launch to market leader status, with sales of €5M in the UK
(NHS) and Ireland (HSE).

 

This appointment is an important milestone ahead of the Company unveiling the
UK's first 100% of lab-grown fillet this year, produced using City-mix™.
This will be used as a showcase to potential customers such as manufacturers,
distributors and wholesalers that are looking to commercialise lab-grown meat
and leather for the mass market.

 

3DBT is already in discussions with a range of significant manufacturers
across the US, Europe, Israel and China and Mr. Brownlee will be responsible
for advancing these and new relationships to commercial partnership status.
Of particular interest to these parties is the fact that, unlike current
growth agents on the market, which are comprised of stem cells and animal
by-products, City-mix™ is both animal and cruelty free. Production of
City-mix™ will also be carbon-neutral, creating the potential to transform
both the meat and leather industries towards net-zero targets.

Che Connon, Chief Executive of 3D-Bio Tissues, said:

"We are absolutely delighted to welcome Robert to the 3DBT team. Our
proprietary City-mix™ growth agent provides the opportunity to make
lab-grown meat and leather truly cruelty-free, as well more affordable and
less carbon-intensive. With our first piece of showcase 100% lab-grown fillet
on track for production over the coming months, and our production capacity
for City-mix™ ramping up, Rob's experience of implementing successful sales
strategies for some of the largest, biotech and pharmaceutical markets across
the UK, Ireland, Europe and the US will be vital in commercialising our
exciting technology."

Robert Brownlee added:

"I have been following the success of 3DBT and am very excited to join such an
innovative and pioneering company. Cellular agriculture represents a very real
means of protecting the environment and driving sustainability. I am looking
forward to helping 3DBT bring its impactful solutions to the market and
building on the team's strong track record of success."

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 BSF Enterprise PLC                      Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Che Connon - Executive Director

 Shard Capital (Broker)
 Damon Heath                             0203 971 7000

 SEC Newgate (Financial Communications)
 Bob Huxford                             020 3757 6882

 Elisabeth Cowell                        BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLMMPTMTTTBIT